<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727738</url>
  </required_header>
  <id_info>
    <org_study_id>UPisa</org_study_id>
    <nct_id>NCT02727738</nct_id>
  </id_info>
  <brief_title>Treatment of Graves' Hyperthyroidism With Selenium Plus Methimazole</brief_title>
  <official_title>Randomized Open Clinical Study to Evaluate the Efficacy of Selenium Plus Methimazole for Treatment of Graves' Hyperthyroidism</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pisa</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pisa</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluation of the efficacy of the combined treatment (methimazole plus selenium) in the
      control of hyperthyroidism as compared to methimazole alone in 30 Graves' disease (GD)
      untreated patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      30 untreated GD hyperthyroid patients will be randomized into two groups (A and B). Group A
      patients will be treated with an anti-thyroid drug (methimazole) at the dose aimed to control
      hyperthyroidism. Group B patients will be treated with methimazole plus selenium (160 mg
      daily). Patients will be evaluated at time 0, 45 and 90 days for symptoms of hyperthyroidism
      (by a specific questionnaire), clinical status (weight, heart rate), laboratory (thyroid
      function tests, TSHR autoantibodies, serum selenium, index of oxidative stress-MDA,
      cholesterol, SHBG) and EKG. The aim of the study is to evaluate if the combined treatment
      (methimazole plus selenium) is more effective than methimazole alone in controlling GD
      hyperthyroidism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">December 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Control of hyperthyroidism</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of FT3 and FT4 values (pg/ml) between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-1</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of heart rate between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-2</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of BMI between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-3</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of total serum cholesterol between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-4</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of total serum sex hormone binding globulin between groups</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-5</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of subjective hyperthyroidism symptoms score collected by questionnaire between groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Control of hyperthyroidism</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of FT3 and FT4 values (pg/ml) between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-1</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of heart rate between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selenium levels</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of serum selenium levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Selenium levels</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of serum selenium levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress parameters-1</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of serum malondialdehyde levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress parameters-2</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of serum glutathione peroxidase levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid autoimmunity-1</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of serum anti-thyroperoxidase antibodies levels and prevalence between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid autoimmunity-2</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of serum anti-thyrotropin receptor antibodies levels and prevalence between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress parameters-1</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of serum malondialdehyde levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress parameters-2</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of serum glutathione peroxidase levels between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid autoimmunity-1</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of serum anti-thyroperoxidase antibodies levels and prevalence between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Thyroid autoimmunity</measure>
    <time_frame>90 days</time_frame>
    <description>Comparison of serum anti-thyrotropin receptor antibodies levels and prevalence between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of selenium</measure>
    <time_frame>45 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events of selenium</measure>
    <time_frame>90 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical manifestatations of hyperthyroidism-2</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of BMI between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-3</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of total serum sex hormone binding globulin between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical manifestations of hyperthyroidism-4</measure>
    <time_frame>45 days</time_frame>
    <description>Comparison of subjective hyperthyroidism symptoms score collected by questionnaire between groups</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Graves' Disease</condition>
  <arm_group>
    <arm_group_label>Methimazole plus selenium</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methimazole 5-30 mg daily for 90 days Selenium 80 bid for 90 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methimazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Methimazole 5-30 mg daily for 90 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Selenium</intervention_name>
    <description>Selenium 80 mg bid for 90 days</description>
    <arm_group_label>Methimazole plus selenium</arm_group_label>
    <other_name>Syrel</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methimazole</intervention_name>
    <description>Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values &lt;10 pg/ml, 10-15 pg/ml, &gt;15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal</description>
    <arm_group_label>Methimazole plus selenium</arm_group_label>
    <arm_group_label>Methimazole</arm_group_label>
    <other_name>Tapazole</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Hyperthyroid untreated Graves' disease patients

        Exclusion Criteria:

          -  Hyperthyroid treated Graves' disease patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claudio Marcocci, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Clinical and Experimental Medicine, University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Endocrinology Unit</name>
      <address>
        <city>Pisa</city>
        <state>PI</state>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2015</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 5, 2016</study_first_posted>
  <last_update_submitted>April 4, 2016</last_update_submitted>
  <last_update_submitted_qc>April 4, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pisa</investigator_affiliation>
    <investigator_full_name>Marin√≤ Michele</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Hyperthyroidism</keyword>
  <keyword>Methimazole</keyword>
  <keyword>Selenium</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graves Disease</mesh_term>
    <mesh_term>Hyperthyroidism</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Selenium</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

